Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - abacavir sulfate,lamivudine -

Zimbabwe - English - Medicines Control Authority

mylan laboratories limited - abacavir sulfate; lamivudine - tablet; oral - 60; 30mg

Zimbabwe - English - Medicines Control Authority

aurobindo pharma limited - abacavir sulfate; lamivudine - tablet, coated; oral - 600; 300mg

Zimbabwe - English - Medicines Control Authority

aurobindo pharma limited - abacavir sulfate; lamivudine - tablet, coated; oral - 60; 30mg

Zimbabwe - English - Medicines Control Authority

mylan laboratories limited - abacavir sulfate; lamivudine - tablet; oral - 120; 60mg

Uganda - English - National Drug Authority

mylan laboratories limited - abacavir sulfate + lamivudine - oral solid ordinary tablets - 600 mg + 300 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: - who have the hla‑b*5701 allele [see warnings and precautions ( 5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions ( 5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations ( 8.7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses

United States - English - NLM (National Library of Medicine)

viiv healthcare company - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir 600 mg - epzicom, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection. epzicom is contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to epzicom during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of miscarri

Kenya - English - Pharmacy and Poisons Board

aurobindo pharma limited plot no. 11, survey 9, hitech city, hyderabad - abacavir sulfate & lamivudine - tablet - each tablet contains abacarvir sulfate 60mg and… - antivirals for systemic use:

Kenya - English - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - abacavir sulfate lamivudine lopinavir ritonavir - capsule - abacavir sulfate usp equivalent to… - antivirals for systemic use: combinations of